Compare HOLX & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLX | WST |
|---|---|---|
| Founded | 1985 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 18.5B |
| IPO Year | 1995 | 2004 |
| Metric | HOLX | WST |
|---|---|---|
| Price | $76.02 | $261.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $77.89 | ★ $319.43 |
| AVG Volume (30 Days) | ★ 8.2M | 772.5K |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.33% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | 0.79 | ★ 6.79 |
| Revenue | ★ $4,100,500,000.00 | $2,886,900,000.00 |
| Revenue This Year | $4.74 | $6.76 |
| Revenue Next Year | $5.03 | $6.25 |
| P/E Ratio | $96.23 | ★ $39.22 |
| Revenue Growth | 1.74 | ★ 1.95 |
| 52 Week Low | $51.90 | $193.05 |
| 52 Week High | $76.07 | $322.34 |
| Indicator | HOLX | WST |
|---|---|---|
| Relative Strength Index (RSI) | 69.09 | 62.02 |
| Support Level | $75.10 | $253.53 |
| Resistance Level | N/A | $261.98 |
| Average True Range (ATR) | 0.19 | 7.14 |
| MACD | 0.03 | 2.37 |
| Stochastic Oscillator | 95.19 | 81.22 |
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.